Published July 3, 2018 | Version v1
Journal article Open

Resistance to ceftaroline - 2018 review

  • 1. Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
  • 2. Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce,
  • 3. Faculty of Medical Science, Higher School of Economics, Law and Medical Science of Professor Edward Lipiński, Kielce, Poland


Ceftaroline is a new fifth generation cephalosporin, active mostly against Gram-positive cocci, e.g. Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus). It is used in treating acute bacterial skin and skin structure infections, community acquired respiratory tract infections and methicillin-resistant S. aureus bacteremia. The main resistance mechanisms of bacteria to β-lactam antibiotics, including ceftaroline, are mutations in PBP2a, PBP3 and PBP4. Clinically significant resistance has been noted among both archived and newly-isolated strains in a laboratory test using serial passages. Ceftaroline-resistant strains have also been found in patients suffering from cystic fibrosis, ventilator-associated pneumonia and infectious endocarditis. Irresponsible antibiotic treatment using ceftaroline or other antibiotics (due to a possibility of a cross-resistance) can lead to the spread of ceftaroline resistance and, consequently, its loss of value.



Files (141.0 kB)

Name Size Download all
141.0 kB Preview Download

Additional details

Related works

Is cited by
2449-8955 (ISSN)